1. Slovenia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Krka, d. d., Novo mesto

Krka, d. d., Novo mesto

1,120.00
PLN
-2.00
(-0.18%)
19.76P/E
Dec 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
36.39
36.37
35.78
36.24
39.31
41.62
47.03
48.88
50.21
55.28
58.36
62.03
66.87
64.43
Basic EPS, GAAP
5.24
5.07
4.86
3.35
4.74
5.46
7.73
9.27
9.92
11.69
10.14
11.6
13.21
12.74
Free Cash Flow per Basic Share
4.41
-0.49
5.19
2.84
3.6
6.15
7.52
8.92
10.07
12
2.84
7.98
14.1
11.95
Dividend per Share
1.61
2.1
2.49
2.65
2.75
2.9
3.2
4.24
5
5.63
6.6
7.5
8.25
- -
Book Value per Share
40.51
41.4
43.27
44.69
46.31
48.2
52.74
55.78
61.24
68.33
70.02
72.29
77.69
86.19
Tangible Book Value per Share
36.98
37.71
39.66
41.17
42.86
44.74
49.28
52.35
57.89
65.02
66.71
69
74.41
82.41
Basic Weighted Avg Shares
33
33
33
32
32
32
32
31
31
31
31
31
31
33
Sales/Revenue/Turnover
1,201
1,192
1,165
1,174
1,266
1,332
1,493
1,535
1,566
1,717
1,806
1,910
2,041
2,112
Operating Margin (%)
18.88
23.1
16.93
10.21
15.45
17.33
18.25
25.19
22.65
22.2
21.81
22.16
22.83
24.4
Depreciation Expense
94
98
107
106
108
111
111
112
109
108
105
93
94
95
Net Income, GAAP
173
166
158
108
153
175
246
291
309
363
314
357
403
418
Effective Tax Rate (%)
14.19
5.22
12.47
6.74
13.39
14.1
14.1
14.76
14.97
16.03
14.54
15
18.61
19.23
Profit Margin (%)
14.39
13.95
13.59
9.23
12.05
13.11
16.44
18.96
19.75
21.15
17.38
18.69
19.76
19.78
Working Capital
487
468
530
522
576
653
787
934
1,007
1,146
1,272
1,378
1,483
1,711
LT Debt
- -
- -
- -
- -
- -
- -
10
9
9
8
9
10
14
14
Total Equity
1,333
1,352
1,406
1,444
1,488
1,540
1,668
1,752
1,919
2,139
2,182
2,238
2,377
2,629
Return on Invested Capital (%)
15.13
19.39
12.51
7.92
11.62
13.18
14.63
19.08
15.8
15.19
15.38
16.18
16.34
15.9
Return on Capital (%)
13.34
12.22
11.34
7.62
10.38
11.61
15.34
17.02
16.36
17.4
14.48
16.12
17.58
16.4
Return on Common Equity (%)
13.45
12.4
11.49
7.62
10.42
11.55
15.34
17.08
16.95
18.06
14.67
16.3
17.62
16.38

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
14
14
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
6,173
7,098
7,622

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,983
2,119
2,244
Cash, Cash Equivalents & STI
688
747
831
Accounts Receivable, Net
610
692
690
Inventories
613
599
605
Total Current Liabilities
500
524
533
Payables & Accruals
- -
- -
- -
ST Debt
4
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.44%
6.36%
6.23%
Free Cash Flow
29.73%
41.74%
75.2%
Net Income, GAAP
11.96%
7.37%
12.96%
Sales/Revenue/Turnover
5.82%
5.9%
6.89%
Total Cash Common Dividend
12.24%
13.62%
9.13%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
486
499
449
475
1,910
2025
522
526
485
507
2,041
2026
566
554
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.21
- -
- -
- -
11.6
2025
4.97
- -
- -
- -
13.21
2026
3.69
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
7.5
2025
- -
- -
- -
- -
8.25
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jože Colaric
Full Time Employees
13,236
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Šmarješka cesta 6 Novo Mesto NM Slovenia 8501
IPO Date
Feb 10, 1997
Website
krka.biz
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Krka, d. d., Novo mesto (KRK.WA) is an international generic pharmaceutical company that develops, produces, markets and sells prescription pharmaceuticals, non-prescription products, animal health products and health resort and tourist services. Prescription pharmaceuticals, its core product group accounting for over 80% of sales, encompass treatments for cardiovascular diseases including perindopril-, valsartan-, losartan-, statin- and rosuvastatin-based medicines; alimentary tract and metabolism disorders; central nervous system conditions; pain management; diabetes; oncology; systemic infections; blood and blood-forming organ diseases; urinary tract disorders; and respiratory system diseases, with innovative forms such as prolonged-release tablets, matrix tablets, osmotic-controlled release systems and pellet-filled capsules; non-prescription products include cough and cold remedies, vitamins and minerals, analgesics, allergy medications, alimentary tract treatments, metabolic disorder drugs and memory/concentration enhancers; animal health products comprise antiparasitics, analgesics, antimicrobials, disinfectants, vitamins and minerals for pets and farm animals; health resort services through subsidiary Terme Krka Group provide medical rehabilitation for cardiovascular, respiratory and mobility issues at facilities including Terme Dolenjske Toplice, Terme Šmarješke Toplice, Talaso Strunjan and Otočec Hotels. The company operates production sites in Slovenia (Novo Mesto-Ločna, Bršljin, Krško, Šentjernej, Ljutomer), Russia, Poland, Croatia, Germany and China, with sales in over 70 countries across six regions: East Europe (34%), Central Europe (23%), West Europe (18%), South-East Europe (14%), Slovenia (6%) and Overseas Markets (4%), targeting healthcare systems, patients and veterinarians with affordable, high-quality generics under its own brands. Founded in 1954 and headquartered in Novo Mesto, Slovenia, Krka Group employs around 12,800 people and generated €1.91 billion in 2024 revenue. In recent developments, Krka established Krka Pharma Pvt. Ltd., a 51:49 joint venture with Laurus Labs Ltd. in India in 2024 (registered capital up to €50 million), to build a new API and finished product manufacturing facility in Hyderabad with €30 million total investment, targeting India and non-EU markets and expected completion in two years; launched 22 new products in 2024 including 18 prescription pharmaceuticals; invested €117 million in production upgrades, R&D and infrastructure; presented an updated 2026-2030 development strategy emphasizing chronic disease treatments, supply reliability and sustainability; and raised 2025 guidance to €2.02-2.13 billion sales and €383-405 million net profit amid 7% nine-month revenue growth to €1.53 billion.